etoposide has been researched along with pazopanib in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (85.71) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Backes, M; Bode-Erdmann, S; Greulich, S; Hebart, H; Kaufmann, M; Mahrholdt, H; Ong, P; Ott, G; Schumm, J | 1 |
Kaneko, T; Koike, K; Kurata, T; Motobayashi, M; Nakazawa, Y; Sano, K; Shigemura, T; Sumi, T; Suzuki, S; Watanabe, T | 1 |
Ahn, JS; Ahn, MJ; Jung, SH; Kim, BS; Kim, HG; Lee, KH; Lee, SH; Min, YJ; Park, K; Sun, JM; Yi, SY; Yun, HJ | 1 |
Bhatla, N; Khurana, S; Kumar, L; Kumar, S; Malik, PS; Ray, MD; Sharma, A | 1 |
Chauhan, R; Khurana, S; Kumar, L; Kumar, S; Malik, PS; Mathur, S; Sharma, A; Singh, M; Sreenivas, V | 1 |
1 review(s) available for etoposide and pazopanib
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for etoposide and pazopanib
Article | Year |
---|---|
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Etoposide; Female; Humans; Indazoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Platinum; Progression-Free Survival; Pyrimidines; Small Cell Lung Carcinoma; Sulfonamides; Survival Analysis; Treatment Outcome | 2018 |
Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Progression-Free Survival; Pyrimidines; Quality of Life; Sulfonamides | 2021 |
4 other study(ies) available for etoposide and pazopanib
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Favorable course of pericardial angiosarcoma under paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging.
Topics: Adrenal Cortex Hormones; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Delayed Diagnosis; Diagnostic Errors; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Heart Neoplasms; Hemangiosarcoma; Humans; Ifosfamide; Indazoles; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Myocardium; Paclitaxel; Pericardial Effusion; Pericardiocentesis; Pericarditis; Pericardium; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrimidines; Remission Induction; Sulfonamides; Vincristine | 2012 |
Dramatic Reduction in Tumor Size During 5 Months of Pazopanib Therapy in Combination With Ifosfamide, Carboplatin, and Etoposide in an Early Infant With Progressive Soft Tissue Sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Indazoles; Infant; Male; Pyrimidines; Remission Induction; Sarcoma; Sulfonamides | 2017 |
Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Celecoxib; Cyclophosphamide; Drug Therapy; Etoposide; Female; Humans; Indazoles; India; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyrimidines; Recurrence; Sulfonamides | 2019 |